Werewolf Therapeutics will present three posters on immune therapies at the SITC Annual Meeting, showcasing innovative cancer treatments.
Quiver AI Summary
Werewolf Therapeutics, Inc., a biopharmaceutical company focused on developing therapeutics that activate the immune system to treat cancer and immune-related conditions, announced that it will present three posters at the Society for Immunotherapy of Cancer's 40th Annual Meeting from November 5-9, 2025. The presentations will cover topics such as the combination of WTX-124 and mWTX-330 with IL-2 and IL-12 INDUKINE molecules to enhance antitumor activity in mice, the development of conditional T cell engagers with reduced toxicity, and insights into the pharmacokinetics of the IL-2 INDUKINE prodrug WTX-124. Werewolf is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules aimed at improving immune responses in the tumor microenvironment while minimizing systemic toxicity. The company's leading candidates are WTX-124 and WTX-330, aimed at treating solid tumors, with ongoing advancements in additional therapies, including its first INDUCER candidate targeting STEAP1 for prostate cancer.
Potential Positives
- Werewolf Therapeutics will present three significant posters at the Society for Immunotherapy of Cancer’s 40th Annual Meeting, highlighting their innovative research and developments.
- The presentations will showcase the enhanced antitumor activity of their WTX-124 and mWTX-330 molecules, which may attract attention from industry experts and potential collaborators.
- The focus on conditional T cell engagers and the proprietary PREDATOR® platform demonstrates the company's commitment to pioneering new treatments for cancer and immune-mediated conditions.
- Werewolf's clinical candidates, WTX-124 and WTX-330, are positioned in advanced stages of development, indicating progress in their therapeutic pipeline which could lead to significant market opportunities.
Potential Negatives
- Limited information on the results of the poster presentations may raise concerns about the effectiveness and viability of the company's therapeutics.
- The lack of mentioned collaborations or partnerships could suggest a potential struggle with resource allocation or market penetration strategies.
- Absence of data from clinical trials in the release might indicate that the development stage is still early, which could concern investors about the timeline and potential for returns.
FAQ
What is Werewolf Therapeutics known for?
Werewolf Therapeutics specializes in developing conditionally activated therapeutics to stimulate the immune system for cancer treatment and immune-mediated conditions.
When and where will Werewolf present at SITC 2025?
Werewolf will present three posters at the SITC 40th Annual Meeting, November 5-9, 2025, in National Harbor, Maryland.
What are INDUKINE molecules?
INDUKINE molecules are therapeutics designed to activate immune responses selectively within the tumor microenvironment while remaining inactive in peripheral tissues.
What is the focus of WTX-124 and WTX-330?
WTX-124 and WTX-330 are conditionally activated cytokines aimed at treating various solid tumors through enhanced immune stimulation.
How can I learn more about Werewolf Therapeutics?
Visit Werewolf Therapeutics' official website at www.werewolftx.com for more information about their research and developments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HOWL Insider Trading Activity
$HOWL insiders have traded $HOWL stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HOWL stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 3 purchases buying 536,426 shares for an estimated $487,187 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$HOWL Hedge Fund Activity
We have seen 32 institutional investors add shares of $HOWL stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PFM HEALTH SCIENCES, LP removed 2,105,410 shares (-84.0%) from their portfolio in Q2 2025, for an estimated $2,294,896
- RUBRIC CAPITAL MANAGEMENT LP removed 1,333,893 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,453,943
- BLACKROCK, INC. removed 1,309,872 shares (-78.3%) from their portfolio in Q2 2025, for an estimated $1,427,760
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 958,125 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,044,356
- RA CAPITAL MANAGEMENT, L.P. added 536,426 shares (+8.7%) to their portfolio in Q2 2025, for an estimated $584,704
- GEODE CAPITAL MANAGEMENT, LLC removed 389,569 shares (-54.3%) from their portfolio in Q2 2025, for an estimated $424,630
- JANE STREET GROUP, LLC added 374,939 shares (+inf%) to their portfolio in Q2 2025, for an estimated $408,683
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HOWL Analyst Ratings
Wall Street analysts have issued reports on $HOWL in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 08/25/2025
- JMP Securities issued a "Market Outperform" rating on 08/21/2025
- Wedbush issued a "Outperform" rating on 05/09/2025
To track analyst ratings and price targets for $HOWL, check out Quiver Quantitative's $HOWL forecast page.
$HOWL Price Targets
Multiple analysts have issued price targets for $HOWL recently. We have seen 3 analysts offer price targets for $HOWL in the last 6 months, with a median target of $6.0.
Here are some recent targets:
- Jason Zemansky from B of A Securities set a target price of $8.0 on 08/25/2025
- Reni J. Benjamin from JMP Securities set a target price of $3.0 on 08/21/2025
- Robert Driscoll from Wedbush set a target price of $6.0 on 05/09/2025
Full Release
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.
Details for the poster presentations are as follows:
Title
: Sequential administration of WTX-124 and mWTX-330, IL-2 and IL-12 INDUKINE™ molecules, enhanced antitumor activity in mice bearing poorly immunogenic EMT6 tumors without systemic toxicity
Abstract Number
: 861
Session Date and Time
: Nov. 7, 2025; 12:15-1:45, 5:10-6:35 p.m.
Location
: Poster Hall (Exhibit Halls A and B1)
Title
: Development of conditional T cell engagers (INDUCER™ molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity
Abstract Number
: 964
Session Date and Time
: Nov. 8, 2025; 12:15-1:45, 5:10-6:35 p.m.
Location
: Poster Hall (Exhibit Halls A and B1)
Title
: Pharmacokinetic insight into the IL-2 INDUKINE prodrug WTX-124: real-time assessment of tumor-specific activation and immune modulation
Abstract Number
: 862
Session Date and Time
: Nov. 8, 2025; 12:15-1:45, 5:10- 6:35 p.m.
Location
: Poster Hall (Exhibit Halls A and B1)
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR ® platform to design conditionally activated INDUKINE™ and INDUCER™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple solid tumor types as a single agent. Werewolf is leveraging positive data from its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf’s first INDUCER development candidate, WTX-1011, targets STEAP1 for prostate cancer. To learn more visit www.werewolftx.com .
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™, INDUCER™, and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact:
Dan Ferry
LifeSci Advisors
617.430.7576
[email protected]
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
[email protected]
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
[email protected]
